Integrinβ6-targeted  ||| S:0 E:20 ||| FW
immunoliposomes  ||| S:20 E:36 ||| FW
mediate  ||| S:36 E:44 ||| FW
tumor-specific  ||| S:44 E:59 ||| JJ
drug  ||| S:59 E:64 ||| NN
delivery  ||| S:64 E:73 ||| NN
and  ||| S:73 E:77 ||| CC
enhance  ||| S:77 E:85 ||| VB
therapeutic  ||| S:85 E:97 ||| JJ
efficacy  ||| S:97 E:106 ||| NN
in  ||| S:106 E:109 ||| IN
colon  ||| S:109 E:115 ||| FW
carcinoma  ||| S:115 E:125 ||| FW
Adjuvant  ||| S:125 E:134 ||| FW
chemotherapy  ||| S:134 E:147 ||| FW
is  ||| S:147 E:150 ||| VBZ
one  ||| S:150 E:154 ||| CD
of  ||| S:154 E:157 ||| IN
the  ||| S:157 E:161 ||| DT
significant  ||| S:161 E:173 ||| JJ
treatments  ||| S:173 E:184 ||| NNS
for  ||| S:184 E:188 ||| IN
colon  ||| S:188 E:194 ||| NN
cancer  ||| S:194 E:201 ||| NN
in  ||| S:201 E:204 ||| IN
clinic ||| S:204 E:210 ||| NN
.  ||| S:210 E:212 ||| .
However ||| S:212 E:219 ||| RB
,  ||| S:219 E:221 ||| ,
it  ||| S:221 E:224 ||| PRP
does  ||| S:224 E:229 ||| VBZ
not  ||| S:229 E:233 ||| RB
achieve  ||| S:233 E:241 ||| VB
the  ||| S:241 E:245 ||| DT
desired  ||| S:245 E:253 ||| JJ
therapeutic  ||| S:253 E:265 ||| JJ
efficacy ||| S:265 E:273 ||| NN
,  ||| S:273 E:275 ||| ,
largely  ||| S:275 E:283 ||| RB
due  ||| S:283 E:287 ||| JJ
to  ||| S:287 E:290 ||| TO
chemotherapeutic  ||| S:290 E:307 ||| VB
resistance ||| S:307 E:317 ||| NN
.  ||| S:317 E:319 ||| .
Integrinβ6  ||| S:319 E:330 ||| NNP
( ||| S:330 E:331 ||| -LRB-
ITGB6 ||| S:331 E:336 ||| NNP
)  ||| S:336 E:338 ||| -RRB-
is  ||| S:338 E:341 ||| VBZ
expressed  ||| S:341 E:351 ||| VBN
in  ||| S:351 E:354 ||| IN
malignant  ||| S:354 E:364 ||| JJ
colonic  ||| S:364 E:372 ||| JJ
epithelia ||| S:372 E:381 ||| NN
,  ||| S:381 E:383 ||| ,
but  ||| S:383 E:387 ||| CC
not  ||| S:387 E:391 ||| RB
in  ||| S:391 E:394 ||| IN
normal  ||| S:394 E:401 ||| JJ
epithelia ||| S:401 E:410 ||| NN
,  ||| S:410 E:412 ||| ,
and  ||| S:412 E:416 ||| CC
is  ||| S:416 E:419 ||| VBZ
associated  ||| S:419 E:430 ||| VBN
with  ||| S:430 E:435 ||| IN
the  ||| S:435 E:439 ||| DT
progression ||| S:439 E:450 ||| NN
,  ||| S:450 E:452 ||| ,
metastasis ||| S:452 E:462 ||| NN
,  ||| S:462 E:464 ||| ,
and  ||| S:464 E:468 ||| CC
chemotherapeutic  ||| S:468 E:485 ||| JJ
resistance  ||| S:485 E:496 ||| NN
of  ||| S:496 E:499 ||| IN
colon  ||| S:499 E:505 ||| NN
cancer ||| S:505 E:511 ||| NN
.  ||| S:511 E:513 ||| .
Accordingly ||| S:513 E:524 ||| RB
,  ||| S:524 E:526 ||| ,
it  ||| S:526 E:529 ||| PRP
is  ||| S:529 E:532 ||| VBZ
necessary  ||| S:532 E:542 ||| JJ
to  ||| S:542 E:545 ||| TO
design  ||| S:545 E:552 ||| VB
therapeutic  ||| S:552 E:564 ||| JJ
approaches  ||| S:564 E:575 ||| NNS
for  ||| S:575 E:579 ||| IN
efficient  ||| S:579 E:589 ||| JJ
and  ||| S:589 E:593 ||| CC
targeted  ||| S:593 E:602 ||| JJ
drug  ||| S:602 E:607 ||| NN
delivery  ||| S:607 E:616 ||| NN
into  ||| S:616 E:621 ||| IN
ITGB6-positive  ||| S:621 E:636 ||| CD
cancer  ||| S:636 E:643 ||| NN
cells  ||| S:643 E:649 ||| NNS
to  ||| S:649 E:652 ||| TO
improve  ||| S:652 E:660 ||| VB
chemotherapeutic  ||| S:660 E:677 ||| JJ
efficacy  ||| S:677 E:686 ||| NN
in  ||| S:686 E:689 ||| IN
colon  ||| S:689 E:695 ||| NN
cancer ||| S:695 E:701 ||| NN
.  ||| S:701 E:703 ||| .
PEGylated  ||| S:703 E:713 ||| JJ
liposomes  ||| S:713 E:723 ||| NN
were  ||| S:723 E:728 ||| VBD
employed  ||| S:728 E:737 ||| VBN
to  ||| S:737 E:740 ||| TO
design  ||| S:740 E:747 ||| VB
ITGB6-targeted  ||| S:747 E:762 ||| CD
immunoliposomes ||| S:762 E:777 ||| NN
,  ||| S:777 E:779 ||| ,
which  ||| S:779 E:785 ||| WDT
have  ||| S:785 E:790 ||| VBP
ITGB6  ||| S:790 E:796 ||| RB
monoclonal  ||| S:796 E:807 ||| JJ
antibodies  ||| S:807 E:818 ||| NNS
( ||| S:818 E:819 ||| -LRB-
mAbs ||| S:819 E:823 ||| NNP
)  ||| S:823 E:825 ||| -RRB-
conjugated ||| S:825 E:835 ||| NN
.  ||| S:835 E:837 ||| .
We  ||| S:837 E:840 ||| PRP
evaluated  ||| S:840 E:850 ||| VBD
the  ||| S:850 E:854 ||| DT
ITGB6-targeted  ||| S:854 E:869 ||| JJ
immunoliposomes  ||| S:869 E:885 ||| JJ
internalization  ||| S:885 E:901 ||| NN
into  ||| S:901 E:906 ||| IN
colon  ||| S:906 E:912 ||| NN
cancer  ||| S:912 E:919 ||| NN
cells  ||| S:919 E:925 ||| NNS
and  ||| S:925 E:929 ||| CC
examined  ||| S:929 E:938 ||| JJ
5-fluorouracil  ||| S:938 E:953 ||| NN
( ||| S:953 E:954 ||| -LRB-
5-FU ||| S:954 E:958 ||| NNP
) ||| S:958 E:959 ||| -RRB-
-induced  ||| S:959 E:968 ||| JJ
cellular  ||| S:968 E:977 ||| JJ
apoptosis  ||| S:977 E:987 ||| NNS
produced  ||| S:987 E:996 ||| VBN
by  ||| S:996 E:999 ||| IN
ITGB6-targeted  ||| S:999 E:1014 ||| CD
immunoliposomes+5-FU ||| S:1014 E:1034 ||| CD
.  ||| S:1034 E:1036 ||| .
In  ||| S:1036 E:1039 ||| IN
addition ||| S:1039 E:1047 ||| NN
,  ||| S:1047 E:1049 ||| ,
the  ||| S:1049 E:1053 ||| DT
biodistribution  ||| S:1053 E:1069 ||| NN
and  ||| S:1069 E:1073 ||| CC
antitumor  ||| S:1073 E:1083 ||| JJ
efficiency  ||| S:1083 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
ITGB6-targeted  ||| S:1097 E:1112 ||| CD
immunoliposomes  ||| S:1112 E:1128 ||| NNS
were  ||| S:1128 E:1133 ||| VBD
observed  ||| S:1133 E:1142 ||| VBN
in  ||| S:1142 E:1145 ||| IN
vivo ||| S:1145 E:1149 ||| NN
.  ||| S:1149 E:1151 ||| .
ITGB6-targeted  ||| S:1151 E:1166 ||| NNP
immunoliposomes  ||| S:1166 E:1182 ||| VBD
enhanced  ||| S:1182 E:1191 ||| VBN
cellular  ||| S:1191 E:1200 ||| JJ
internalization  ||| S:1200 E:1216 ||| NN
in  ||| S:1216 E:1219 ||| IN
ITGB6-positive  ||| S:1219 E:1234 ||| CD
colon  ||| S:1234 E:1240 ||| NN
cancer  ||| S:1240 E:1247 ||| NN
cells  ||| S:1247 E:1253 ||| NNS
compared  ||| S:1253 E:1262 ||| VBN
with  ||| S:1262 E:1267 ||| IN
liposomes ||| S:1267 E:1276 ||| NN
.  ||| S:1276 E:1278 ||| .
Furthermore ||| S:1278 E:1289 ||| RB
,  ||| S:1289 E:1291 ||| ,
the  ||| S:1291 E:1295 ||| DT
ITGB6-targeted  ||| S:1295 E:1310 ||| CD
immunoliposome  ||| S:1310 E:1325 ||| CD
internalization  ||| S:1325 E:1341 ||| NNS
was  ||| S:1341 E:1345 ||| VBD
dependent  ||| S:1345 E:1355 ||| JJ
on  ||| S:1355 E:1358 ||| IN
the  ||| S:1358 E:1362 ||| DT
ITGB6  ||| S:1362 E:1368 ||| JJ
expression  ||| S:1368 E:1379 ||| NN
level  ||| S:1379 E:1385 ||| NN
on  ||| S:1385 E:1388 ||| IN
cellular  ||| S:1388 E:1397 ||| JJ
surface ||| S:1397 E:1404 ||| NN
.  ||| S:1404 E:1406 ||| .
ITGB6-targeted  ||| S:1406 E:1421 ||| NNP
immunoliposomes  ||| S:1421 E:1437 ||| NN
decreased  ||| S:1437 E:1447 ||| VBD
the  ||| S:1447 E:1451 ||| DT
5-FU  ||| S:1451 E:1456 ||| CD
IC50  ||| S:1456 E:1461 ||| CD
more  ||| S:1461 E:1466 ||| JJR
than  ||| S:1466 E:1471 ||| IN
90 ||| S:1471 E:1473 ||| CD
%  ||| S:1473 E:1475 ||| NN
in  ||| S:1475 E:1478 ||| IN
HT-29  ||| S:1478 E:1484 ||| NNP
and  ||| S:1484 E:1488 ||| CC
SW480β6  ||| S:1488 E:1496 ||| CD
cells  ||| S:1496 E:1502 ||| NNS
relative  ||| S:1502 E:1511 ||| JJ
to  ||| S:1511 E:1514 ||| TO
liposomes ||| S:1514 E:1523 ||| VB
.  ||| S:1523 E:1525 ||| .
Moreover ||| S:1525 E:1533 ||| RB
,  ||| S:1533 E:1535 ||| ,
when  ||| S:1535 E:1540 ||| WRB
loaded  ||| S:1540 E:1547 ||| VBN
with  ||| S:1547 E:1552 ||| IN
5-FU ||| S:1552 E:1556 ||| NNP
,  ||| S:1556 E:1558 ||| ,
ITGB6-targeted  ||| S:1558 E:1573 ||| CD
immunoliposomes  ||| S:1573 E:1589 ||| NNS
produced  ||| S:1589 E:1598 ||| VBD
an  ||| S:1598 E:1601 ||| DT
approximately  ||| S:1601 E:1615 ||| RB
1.5-fold  ||| S:1615 E:1624 ||| CD
higher  ||| S:1624 E:1631 ||| JJR
5-FU-induced  ||| S:1631 E:1644 ||| JJ
cellular  ||| S:1644 E:1653 ||| JJ
apoptosis  ||| S:1653 E:1663 ||| JJ
rate  ||| S:1663 E:1668 ||| NN
than  ||| S:1668 E:1673 ||| IN
liposomes ||| S:1673 E:1682 ||| NN
.  ||| S:1682 E:1684 ||| .
In  ||| S:1684 E:1687 ||| IN
vivo ||| S:1687 E:1691 ||| NN
,  ||| S:1691 E:1693 ||| ,
the  ||| S:1693 E:1697 ||| DT
therapeutic  ||| S:1697 E:1709 ||| JJ
activity  ||| S:1709 E:1718 ||| NN
of  ||| S:1718 E:1721 ||| IN
ITGB6-targeted  ||| S:1721 E:1736 ||| NNP
immunoliposomes+5-FU  ||| S:1736 E:1757 ||| NNP
was  ||| S:1757 E:1761 ||| VBD
significantly  ||| S:1761 E:1775 ||| RB
superior ||| S:1775 E:1783 ||| JJ
,  ||| S:1783 E:1785 ||| ,
resulting  ||| S:1785 E:1795 ||| VBG
in  ||| S:1795 E:1798 ||| IN
25 ||| S:1798 E:1800 ||| CD
%  ||| S:1800 E:1802 ||| NN
to  ||| S:1802 E:1805 ||| TO
35 ||| S:1805 E:1807 ||| CD
%  ||| S:1807 E:1809 ||| NN
reduction  ||| S:1809 E:1819 ||| NN
of  ||| S:1819 E:1822 ||| IN
tumor  ||| S:1822 E:1828 ||| NN
weight  ||| S:1828 E:1835 ||| NN
compared  ||| S:1835 E:1844 ||| VBN
with  ||| S:1844 E:1849 ||| IN
5-FU  ||| S:1849 E:1854 ||| NNP
or  ||| S:1854 E:1857 ||| CC
liposomes+5-FU ||| S:1857 E:1871 ||| NNP
.  ||| S:1871 E:1873 ||| .
ITGB6-targeted  ||| S:1873 E:1888 ||| NNP
immunoliposomes  ||| S:1888 E:1904 ||| NNS
provide  ||| S:1904 E:1912 ||| VBP
a  ||| S:1912 E:1914 ||| DT
highly  ||| S:1914 E:1921 ||| RB
efficient  ||| S:1921 E:1931 ||| JJ
approach  ||| S:1931 E:1940 ||| NN
for  ||| S:1940 E:1944 ||| IN
targeted  ||| S:1944 E:1953 ||| JJ
drug  ||| S:1953 E:1958 ||| NN
delivery  ||| S:1958 E:1967 ||| NN
in  ||| S:1967 E:1970 ||| IN
colon  ||| S:1970 E:1976 ||| NN
cancer  ||| S:1976 E:1983 ||| NN
and  ||| S:1983 E:1987 ||| CC
thus  ||| S:1987 E:1992 ||| RB
offer  ||| S:1992 E:1998 ||| VB
the  ||| S:1998 E:2002 ||| DT
potential  ||| S:2002 E:2012 ||| NN
of  ||| S:2012 E:2015 ||| IN
a  ||| S:2015 E:2017 ||| DT
novel  ||| S:2017 E:2023 ||| NN
and  ||| S:2023 E:2027 ||| CC
promising  ||| S:2027 E:2037 ||| JJ
anticancer  ||| S:2037 E:2048 ||| JJ
strategy  ||| S:2048 E:2057 ||| NN
for  ||| S:2057 E:2061 ||| IN
clinical  ||| S:2061 E:2070 ||| JJ
therapy ||| S:2070 E:2077 ||| NN
.  ||| S:2077 E:2079 ||| .
